DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God................DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 25Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK GENERICS at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Sunday 8 June 2014

LOPINAVIR

 Lopinavir.svg
LOPINAVIR
(2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
[1S-[1R*,(R*),3R*,4R*]]-N-[4-[[(2,6-dimethyl-phenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S,3S,5S)-2-(-2,6- dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2-(1-tetrahydropyrimid-2-onyl)-3- methylbutanoyl)amino-1 ,6-diphenylhexane
628.8008

Abbott Laboratories
 CAS 192725-17-0
AHFS/Drugs.com International Drug Names
MedlinePlus a602015
Pregnancy cat. C (US)
Legal status POM (UK) -only (US)
DrugSyn.org
US5914332
SYNONYMS
ABT-378, Aluviran, Koletra, ABT 378, 1mui, 2rkf, 2rkg, A 157378.0, RS-346
Molecular Formula: C37H48N4O5   Molecular Weight: 628.80082
Org. Proc. Res. Dev., 2000, 4 (4), pp 264–269
DOI: 10.1021/op990202j
http://pubs.acs.org/doi/abs/10.1021/op990202j
A large scale process for the synthesis of HIV protease inhibitor candidate ABT-378 has been developed which utilizes an intermediate common to the synthesis of ritonavir, Abbott’s first generation compound. The synthesis relies on the sequential acylation of this intermediate which is carried through as a mixture of diastereomers until the penultimate step. A synthesis of acid 5, derived from l-valine, is also reported.
[1S-[1R*(R*),3R*,4R*]]-N-[4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-α-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide (2).
A 500-mL, three-necked, round-bottomed flask equipped with mechanical stirring, ……………………..DELETED…………………The solid product was washed with 30 mL of 1:1 EtOAc/heptane and dried in vacuo at 70 °C for 60 h, affording 18.8 g (89% yield) of ABT-378 2 as a colorless solid. Before crystallization crude 2 assayed as >93% pure by HPLC; after crystallization >99% purity was achieved.
mp (EtOAc), 124−127 °C. (uncorrected)
IR:  3413, 3335, 3289, 3060, 2966, 1671, 1650, 1624, 1545, 1520, 1453, 1189, 701 cm-1.
1H NMR (300 MHz):  δ 7.30−7.13 (m, 10H), 7.02−6.92 (m, 3H), 6.86 (v br s, 1H), 5.68 (br s, 1H), 4.25 (m, 1H), 4.19 (app d, J = 10 Hz, 2H), 4.19 (m, 2H), 3.78 (m, app d sept, 1H), 3.12 (m, 1H), 3.06 (m, 2H), 2.97 (d, J = 7.6 Hz, 2H), 2.88 (m, 1H), 2.81 (app ABX dd, J = 14, 5.2 Hz, 1H), 2.68 (app ABX, dd, J = 14, 9.5 Hz, 1H), 2.23 (m, 1H), 2.18 (s, 6H), 1.83 (s, 1H), 1.74 (m, 2H), 1.53 (m, 1H), 1.28 (m, 2H), 0.83 (app t, J = 7 Hz, 6H).
13C NMR (75 MHz):  δ 170.7, 168.8, 156.5, 154.2, 138.1, 138.0, 130.3, 129,3, 129.2, 129.0, 128.4, 128.2, 126.3, 126.0, 124.6, 70.2, 69.7, 63.1, 54.4, 48.7, 41.8, 41.1, 40.8, 40.0, 38.2, 25.4, 21.7, 19.6, 18.7, 16.1,
MS (ESI) 629 (M + H)+, 651 (M + Na)+.
Anal. Calcd for C37H48N4O5:  C, 70.66; H, 7.69; N 8.91. Found:  C, 70.26; H, 7.73; N 8.79.
[α]d20 = − 22.85 (c 0.4 MeOH).
  • Crystallographic studies have shown, to our surprise, that 2 isolated by this crystallization method is not a solvate.
  • The determination of the enantiomeric excess (% ee) for ABT-378 (2) can be done indirectly. Compound 17, which results from the acylation of 4 with the enantiomer of acid 5, is known to us, having been detected as an impurity in our process development.17 Compound 18 can only result from the acylation of the enantiomer of 4 (2R,3R,5R) with 5. The levels of 17/18 observed in 2 are typically <0.1%. Until there is a need for a more definitive assay, we assume this represents an upper limit to the amount of ent-2 present.
Enantiomeric excess is determined by HPLC (Chiracel OD column, elution with hexane: ethanol: trifluoroacetic acid (930:  70:  1). The desired l-isomer has a retention time of approximately 14 min; the d-isomer, 11.5 min.

References

  1. “FDA Approved Drug Products: Kaletra”. Retrieved 30 April 2004.
  2. KALETRA (lopinavir/ritonavir) capsules; (lopinavir/ritonavir) oral solution. Prescribing information. April 2009
  3. Capparelli E, Holland D, Okamoto C, et al. (2005). “Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV”. AIDS (London, England) 19 (9).
  4. HIV drug used to reverse effects of virus that causes cervical cancer University of Manchester, 17 February 2014.

 

8-20-2003
Crystalline pharmaceutical
12-27-2002
Compositions and methods for enhancing the
bioavailability of pharmaceutical agents
10-13-2000
PREGELATINIZED STARCH IN A CONTROLLED
 RELEASE FORMULATION
6-20-1997
RETROVIRAL PROTEASE INHIBITING COMPOUNDS

8-8-2012
PROCESS FOR THE PREPARATION OF SUBSTANTIALLY
 PURE (2S,3S,5S)-5-AMINO-2-N,N-DIBENZYLAMINO-3-
HYDROXY-1,6-DIPHENYLHEXANE
11-12-2010
PRODRUGS OF HIV PROTEASE INHIBITORS
5-19-2010
Prodrugs of HIV protease inhibitors
5-7-2010
DIMETHYLPHENOXY MODULATORS OF VIRAL
 PROTEASE ACTIVITY AND/OR PARASITIC ENZYME ACTIVITY
1-12-2007
Methods of treating cancer
9-21-2005
Method to design therapeutically important compounds
6-10-2005
Crystalline pharmaceutical
3-9-2005
Crystalline pharmaceutical
2-4-2005
Methods and compositions for the treatment or prevention
of human immunodeficiency virus and related conditions
using cyclooxygenase-2 selective inhibitors and
antiviral agents
8-27-2004
Methods of treating cancer

No comments:

Post a Comment